Soleno Therapeutics, Inc.
SLNO · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.12 | 6.87 | 0.07 | -0.11 |
| FCF Yield | -3.84% | -3.76% | -25.01% | -17.00% |
| EV / EBITDA | -10.20 | -13.35 | -3.14 | -4.97 |
| Quality | ||||
| ROIC | -58.97% | -24.42% | -105.66% | -107.26% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.39 | 0.64 | 0.86 | 0.90 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -177.92% | -19.94% | 25.18% | -10.15% |
| Safety | ||||
| Net Debt / EBITDA | 0.20 | 4.57 | 0.66 | 0.73 |
| Interest Coverage | -798.39 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,631.57 | -587.02 | -293.49 | -538.16 |